Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First in Human Feasibility Study With ADAPT 3D - ALR for Aortic Leaflet Repair

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04178213
Recruitment Status : Recruiting
First Posted : November 26, 2019
Last Update Posted : February 16, 2022
Sponsor:
Collaborator:
Factory CRO for Medical Devices B.V.
Information provided by (Responsible Party):
Admedus Regen Pty Ltd.

Brief Summary:
This study will evaluate the safety and performance of the ADAPT 3D - ALR in adult patients requiring replacement of aortic valve. 15 patients in one site in Belgium will all be treated with ADAPT 3D - ALR.

Condition or disease Intervention/treatment Phase
Aortic Stenosis Aortic Insufficiency Device: Implantation of ADAPT 3D ALR Not Applicable

Detailed Description:

The purpose of this study is to conduct the initial clinical investigation of single piece ADAPT treated 3D - ALR (Aortic Leaflet Repair) to collect evidence on the device's safety and performance. The study is anticipated to confirm successful clinical safety and clinical performance with significant improvements in clinical hemodynamic performance.

The ADAPT® technology is used to process animal derived tissues to produce implantable tissue prosthetic devices that are compatible with the human body. This technology has been shown to produce reliable, biocompatible and versatile regenerative prosthetic devices capable of being used instead of synthetic products currently used in many soft tissue repair applications.

15 patients with aortic valve insufficiency or stenosis will be enrolled in this single arm single site study.

Follow-up will continue through to 26 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: prospective, non-randomised, single arm, single-centre First In Human clinical investigation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First in Human Surgical Implantation of Single Piece ADAPT® Treated 3D ALR (Aortic Leaflet Repair), Feasibility and Clinical Safety Study
Actual Study Start Date : March 26, 2020
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ADAPT 3D ALR
Patients treated with ADAPT 3D ALR
Device: Implantation of ADAPT 3D ALR
The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.




Primary Outcome Measures :
  1. mean pressure gradient (mmHg) across the valve (less than 20 mmHg) [ Time Frame: 6 months following implantation ]
    Hemodynamic Performance Assessment

  2. derived Effective Orifice Area (EOA) range > 0.9 cm2 (19mm valve) to > 1.6 cm2 (27mm valve) [ Time Frame: 6 months following implantation ]
    Hemodynamic Performance Assessment

  3. rate of thromboembolism [ Time Frame: 6 months following implantation ]
    The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard.

  4. rate of valve thrombosis [ Time Frame: 6 months following implantation ]
    The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard.

  5. rate of major paravalvular leak [ Time Frame: 6 months following implantation ]
    The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard.

  6. rate of major hemorrhage [ Time Frame: 6 months following implantation ]
    The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard.

  7. rate of endocarditis [ Time Frame: 6 months following implantation ]
    The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard.


Secondary Outcome Measures :
  1. Rate of Atrial Fibrillation 6 months post procedure [ Time Frame: 6 months post procedure ]
    New/post-operative atrial fibrillation - confirmed on ECG after closure till 6 months

  2. number of days in ICU [ Time Frame: 30 days post procedure ]
    Length of stay in the ICU post valve implantation defined as arrival time/date in hours and minutes to transfer to ward time/date in hours and minutes.

  3. NYHA (New York Heart Association) class Improvement Assessment [ Time Frame: 6 months post procedure ]
    Clinically significant improvement (one grade) in the New York Heart Association (NYHA) functional classification. 4 classes of disease: min value Class IV (cardiac disease resulting in inability to carry on any physical activity without discomfort); max value Class I (cardiac disease but without resulting limitations of physical activity)

  4. number of days in hospital post procedure [ Time Frame: 30 days post procedure ]
    Post procedure length of stay defined as the date and time in hours and minutes documented for arrival in the recovery unit to date and time in hours and minutes of discharge in hours and minutes.

  5. hemoglobin assessment [ Time Frame: 6 months post procedure ]
    Hemolysis screen measured by blood test

  6. Alanine transaminase (ALT) [ Time Frame: 6 months post procedure ]
    Hemolysis screen measured by blood test of liver enzyme

  7. Aspartate transaminase (AST) [ Time Frame: 6 months post procedure ]
    Hemolysis screen measured by blood test of liver enzyme

  8. Rate of all-caused death [ Time Frame: 6 months following implantation ]
    The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature.

  9. Rate of valve related death [ Time Frame: 6 months following implantation ]
    The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature.

  10. Rate of valve-related reoperation [ Time Frame: 6 months following implantation ]
    The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature.

  11. Rate of valve explant [ Time Frame: 6 months following implantation ]
    The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature.

  12. Rate of hemorrhage [ Time Frame: 6 months following implantation ]
    The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature.

  13. Rate of all-cause reoperation [ Time Frame: 6 months following implantation ]
    The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature.

  14. Rate of Device deficiency [ Time Frame: 6 months following implantation ]
    Device deficiency measured by echo



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is older than 18 years of age and ≤ 85 years.
  2. The subject's aortic annular measurements are ≥ 21 mm to < 27mm as confirmed on pre-op echo.
  3. The subject is a candidate for Aortic Valve Replacement.
  4. The subject has documented moderate or severe Aortic Stenosis and/or Aortic Insufficiency (defined as grade 2, 3 or 4).
  5. The subject is willing and able to comply with specified follow-up requirements and evaluations, including transesophageal echocardiography (TEE) if there are inadequate images by transthoracic echocardiography (TTE) to assess the aortic valve.
  6. Patient has signed the informed consent

Exclusion Criteria:

  1. All patients who require emergency surgery (within 24 hours of a presentation to an emergency department) for any reason.
  2. Subject with a pre-existing valve prosthesis in the aortic position.
  3. Patients requiring repair of other cardiac valves will be excluded.
  4. Subject with active endocarditis.
  5. Heavily calcified aortic roots or "porcelain aortas".
  6. Leukopenia with a WBC (white Blood Cells) of less than 3000.
  7. Acute anaemia with a haemoglobin less than 8 g/dL.
  8. Platelet count less than 100,000 platelets/microliter, and if less than 150,000 platelets/microliter, platelet reduction of >10,000 platelets/microliter per day over two consecutive days (Note: Where a platelet count is less than 150,000 platelets/microliter but greater than 100,000 platelets/microliter, platelet count testing is to be conducted over 2 consecutive days. If platelets are reducing over those two consecutive days, the rate of reduction in platelets must be less than 10,000 platelets/microliter per day, otherwise the participant must be excluded).
  9. History of a defined bleeding diathesis or coagulopathy or the subject refuses blood transfusions.
  10. Active infection requiring antibiotic therapy (if temporary illness, subjects may enroll 2-4 weeks after discontinuation of antibiotics).
  11. Subjects in whom transesophageal echocardiography (TEE) is contraindicated.
  12. Low EF < 50 %.
  13. Life expectancy < 1 year, or severe comorbidities, such as cancer, dialysis, or severe COPD.
  14. The subject is an illicit drug user, alcohol abuser, prisoner, institutionalised, or is unable to give informed consent.
  15. The subject is pregnant or lactating (non-pregnancy to be confirmed by pregnancy test for all child bearing potential females).
  16. Recent (within 6 months) cerebrovascular accident (CVA) or a transient ischemic attack (TIA).
  17. Myocardial Infarction (MI) within one month of trial inclusion.
  18. Currently participating in, or have been recently exited from (within 30 days of enrollment in this study), or plan to be enrolled in another clinical

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04178213


Contacts
Layout table for location contacts
Contact: Factory CRO +31 30 229 2727 jurriaan.sombeek@avaniaclinical.com
Contact: Deanna Linden +1 651 493 0606 ext 1012 dlinden@anteristech.com

Locations
Layout table for location information
Belgium
University Hospital Leuven Recruiting
Leuven, Belgium, 3000
Contact: Klaartjie Van den Bossche    +32 16 34 21 60    klaartje.vandenbossche@uzleuven.be   
Sub-Investigator: Peter Verbrugghe         
Sponsors and Collaborators
Admedus Regen Pty Ltd.
Factory CRO for Medical Devices B.V.
Investigators
Layout table for investigator information
Principal Investigator: Bart Meuris, Prof. Dr. Universitaire Ziekenhuizen Leuven
Layout table for additonal information
Responsible Party: Admedus Regen Pty Ltd.
ClinicalTrials.gov Identifier: NCT04178213    
Other Study ID Numbers: GLRA-G012
First Posted: November 26, 2019    Key Record Dates
Last Update Posted: February 16, 2022
Last Verified: February 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Admedus Regen Pty Ltd.:
ADAPT
aortic leaflet repair
aortic valve
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Aortic Valve Insufficiency
Aortic Valve Disease
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction